Gregory Tall and team's study on GPR114/ADGRG5, activated by tethered-peptide-agonist, a cleaved adhesion Submit poster abstracts here; short talks will be selected from Abstracts. substance use disorders Industry News Crinetics’ Once-Daily Oral Paltusotine Achieved The Primary And All Stephen Dowd As Chief Business Officer Septerna Announces Novel GPCR-targeted Program Acquired by Vertex Call

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Dates Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links Registration closing dates: 6th September – registration against invoice (bank transfers): Tuesday, 6th September 30th September – online registration (card payments)" Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany. Hybrid meeting. "Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic intervention. Therefore, the aim of this symposium is to bring together the current knowledge on the role of autoantibodies targeting GPCRs in various diseases, such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus erythematosus. In addition, one aim is to bring together the mode of action of autoantibodies in immune regulation and pathogenesis." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Join Us in Boston for Discovery On Target 2022! Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "WELCOME 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for a joint meeting in Leipzig. Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded SFB1423 and FOR2372) have joined forces to organize an international meeting, which will take place from 26th-29th September 2022 in the beautiful city of Leipzig in Germany. We aim to connect renowned international experts of the field with early career ‘rising stars’. The event will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid social life." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "We are happy to announce you our 2nd IRN i-GPCRnet meeting that will be held at the University of Wurzburg (Germany) from september 30th to october 1rst." Read more at the source #DrGPCR #GPCR #IndustryNews

Profiling Immune Cell and Platelet Transcriptomes , and we want to wish her the best of luck on her talk We all are cheering for you! We aim to make education accessible to all! the science Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med Call

Here, we provide evidence that distal carboxyl-terminal tail (C-tail), but not proximal, phosphorylation site-directed mutagenesis and bioluminescence resonance energy transfer approaches that distal, not proximal, C-tail In addition, we show that GPCRs that have similarly positioned C-tail phosphoresidues are also able to However, although necessary for some GPCRs, we found that distal C-tail sites might not be sufficient In conclusion, this study provides evidence that distal C-tail phosphorylation sites specify GRK-βarrestin-mediated

Bursicon receptor gene HLGR2 as a potential RNA interference target for control of the fall webworm Hyphantria

March 2022 " Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results on Thursday, March 10, 2022. Tim Dyer , CEO, Roger Mills , CMO and Robert Lütjens , Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day. " Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel cannabis, but John Streicher , PhD, takes a closer look at the plant’s aromatic chemical compounds called

Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. Joanne Kamens is our guest. If you need a plasmid for your research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe #addgene

Toll-like receptor 4 (TLR4) is one such non-GPCR receptor, which involves MyD88-dependent and TRIF-dependent

protein constructs GST-CB1414-472 and GST-CB1414-442 containing much of the human CB1 receptor C-terminal tail To this end we used three different antibodies, all raised against a peptide comprising the C-terminal

The all-atom MD simulations reveal that CBD induces conformational changes linked with agonist-bound

Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR China M Payne ,   Cam Sinh Lu ,   Karen Gregory We aim to make education accessible to all! behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Call

., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2016).

The GPCR rocket is all fueled and ready to blast off into a galaxy of incredible advancements, now powered activity-modifying proteins in obesity and diabetes mellitus Maleesha Ubhayarathna , Christopher Langmead , Gregory disorders: Opportunities and hurdles for clinical development 👨‍💻 Why would you want to miss out on all Being a premium member means you get to enjoy all the freebies plus: Access to the recorded classes Exclusive access to private groups  Over 30 recorded talks from Symposia - that's a lot of brain food

GPCR-G protein selectivity revealed by structural pharmacology Yao Lu , Drs Christopher Langmead ,  Gregory

a single compound, resulting in a novel category of GPCR ligands referred to as 'bitopic' (Valant, Gregory

Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations "Allosteric modulators are called raises many questions about the ligand interactions and stability, the binding site structure, and how all Although ligand-lipid interactions are weak, lipid tails play a role in ligand binding pose stability

If you couldn't make it, no sweat – our premium members can always go back and watch the recorded talks Short talk selections will be announced soon. Abstract submissions close on October 2nd. All information is available on the Logo Contest page. Program Receives €4 Million Grant Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer Call

The family of adhesion GPCRs called the Latrophilins or ADGRLs first captured my attention due to their through a suggestion from one of my colleagues to join this select group, which was getting together to talk I still remember entering the Hall at Boston ́s Children Hospital, going to register and being asked Also, seeing the expanding diversity among the aGPCR community, added to the fact that this will all PMID 38421639 Systematic assessment of the tethered agonist-dependent activities of all 33 aGPCRs in

Su , et al. for their fantastic work on Germline mutations in a G protein identify signaling cross-talk Biosciences, INC as a Preferred Supplier at Prendio Crinetics Pharmaceuticals announces executive departure Call research position GPCR Activation and Signaling Germline mutations in a G protein identify signaling cross-talk

Thank you to all participants in Dr. Terry Kenakin's educational initiative this fall! We thank all participants for their inspiring contributions and passion. important drug breakthroughs ever Goldman-backed drug developer Septerna raises $288 mln in US IPO Call

Submit your abstracts for poster presentation using this form - short talks will be selected from these GPCR Activation and Signaling Tail engagement of arrestin at the glucagon receptor Gα protein signaling

💡Trainees are invited to participate by presenting a trainee talk, a poster, or a pre-recorded talk

function of G protein-coupled receptors (GPCRs). βarrs typically interact with phosphorylated C-terminal tail (C tail) and transmembrane core (TM core) of GPCRs. However, the effects of the C tail- and TM core-mediated interactions on the conformational activation Here, we show the conformational changes for βarr activation upon the C tail- and TM core-mediated interactions Our NMR analyses demonstrated that while the C tail-mediated interaction alone induces partial activation